A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

  • Alzheimer's Disease (AD)
Trial Status:

Terminated

This trial runs in
Cities
  • Aarhus
  • Abington
  • Albacete
  • Ankara
  • Austin
  • Barcelona
  • Beaumont
  • bei-jing-shi
  • Beograd
  • Berlin
  • Bordeaux
  • Boston
  • Bradenton
  • Braga
  • Brescia
  • Brugge
  • Buenos Aires
  • Burgos
  • Busan
  • Bydgoszcz
  • Castellanza
  • Castelló de la Plana
  • Cercado de Lima
  • Charlotte
  • Cheltenham
  • Chertsey
  • Chiba
  • Cincinnati
  • Coimbra
  • Colmar
  • Colorado Springs
  • Columbus
  • Crowborough
  • Córdoba
  • Dallas
  • Darlinghurst
  • DCE
  • Distrito Federal
  • Dundee
  • Edinburgh
  • Elche
  • Erina
  • Fayetteville
  • Flowood
  • Fort Myers
  • Frankfurt am Main
  • Freiburg im Breisgau
  • Fujisawa
  • Fukuoka
  • Getxo
  • Glasgow
  • Hachioji
  • Haifa
  • Halifax
  • Himeji
  • Homburg
  • Hornsby
  • Houston
  • Incheon
  • İstanbul
  • itabashi-city
  • Kaohsiung City
  • Kazan
  • Kelowna
  • Kentville
  • Kingston
  • Kodaira
  • Kortrijk
  • Kragujevac
  • Kurashiki
  • Kyoto
  • København
  • Lake Charles
  • Lake Worth
  • Las Vegas
  • Leipzig
  • Leuven
  • Lille
  • Limoges
  • Little Rock
  • Logroño
  • London
  • Longueuil
  • Madrid
  • Manchester
  • Matsumoto
  • Memphis
  • Milano
  • Minas Gerais
  • Mittweida
  • Moscow
  • Mölndal
  • München
  • New Taipei City
  • New York
  • Nizhny Novgorod
  • nordbyhagen
  • Norfolk
  • Norwalk
  • Obu
  • Ocala
  • Ohio
  • Omaha
  • Orlando
  • Oslo
  • Otake
  • Oxford
  • Pamplona
  • Paraná
  • Paris
  • Pasadena
  • Peterborough
  • Philadelphia
  • Pisa
  • Plains
  • Plasencia
  • Port Orange
  • Portland
  • Porto
  • Pozuelo de Alarcón
  • Pozzilli
  • Québec
  • Raleigh
  • Rancho Mirage
  • Redlands
  • Reims
  • Rennes
  • Rho
  • Richmond
  • Rio de Janeiro
  • Rio Grande do Sul
  • Roma
  • Rouen
  • Sacramento
  • Sagamihara
  • Saint Paul
  • Saint Petersburg
  • Saint-Herblain
  • Sakai
  • Salamanca
  • Salt
  • Samsun
  • San Antonio
  • San Francisco
  • San Sebastián-Donostia
  • Sandton
  • Sant Cugat del Vallès
  • Santander
  • Santiago de Compostela
  • Scottsdale
  • Senhora da Hora
  • Seongnam-si
  • Seoul
  • Setagaya City
  • Sevilla
  • Shinjuku City
  • Shizuoka
  • Skåne län
  • Southampton
  • Springfield
  • Stamford
  • Suita
  • Szczecin
  • São Paulo
  • Taipei City
  • Takamatsu
  • Tallinn
  • Taoyuan City
  • Tel Aviv-Yafo
  • Terrassa
  • tian-jin-shi
  • Toms River
  • Tomsk
  • Torino
  • Toronto
  • Victoria
  • Villeurbanne
  • Warszawa
  • Washington
  • Wellington
  • White Plains
  • Woodstock
  • Woodville South
  • Wrocław
  • Yahaba
  • Yekaterinburg
  • באר שבע
Trial Identifier:

NCT03114657 2016-003288-20 BN29553

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT03114657 , BN29553 , 2016-003288-20 Trial Identifier
      Crenezumab, Placebo Treatments
      Alzheimer's Disease Condition
      Official Title

      A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

      Eligibility Criteria

      All Gender
      ≥ 50 Years & ≤ 85 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Weight between 40 and 120 kilograms (Kg) inclusive
      • Availability of a person (referred to as the "caregiver") who in the investigator's judgment:
      • Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities
      • Fluency in the language of the tests used at the study site
      • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
      • Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory
      • Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =<0.67 AND free recall =<27)
      • Screening mini mental state examination (MMSE) score of greater than or equal to (>=) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
      • Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
      • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening
      • Participant must have completed at least 6 years of formal education after the age of 5 years
      Exclusion Criteria
      • Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
      • History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
      • At risk of suicide in the opinion of the investigator
      • Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI
      • Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease
      • Uncontrolled hypertension
      • Screening hemoglobin A1c (HbA1C) >8%
      • Poor peripheral venous access
      • History of cancer except:

      If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy

        - Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now